Shopping Cart 0
Cart Subtotal
USD 0

Tissue Heart Valves - Medical Devices Pipeline Assessment, 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 4000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 8000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 12000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Tissue Heart Valves-Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, Tissue Heart Valves-Medical Devices Pipeline Assessment, 2018 provides an overview of Tissue Heart Valves currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Tissue Heart Valves pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Tissue Heart Valves under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Tissue Heart Valves and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry

Reasons to buy

The report enables you to-

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Tissue Heart Valves under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 6

2 Introduction 7

2.1 Tissue Heart Valves Overview 7

3 Products under Development 8

3.1 Tissue Heart Valves-Pipeline Products by Stage of Development 8

3.2 Tissue Heart Valves-Pipeline Products by Segment 9

3.3 Tissue Heart Valves-Pipeline Products by Territory 10

3.4 Tissue Heart Valves-Pipeline Products by Regulatory Path 11

3.5 Tissue Heart Valves-Pipeline Products by Estimated Approval Date 12

3.6 Tissue Heart Valves-Ongoing Clinical Trials 13

4 Tissue Heart Valves-Pipeline Products under Development by Companies 14

4.1 Tissue Heart Valves Companies-Pipeline Products by Stage of Development 14

4.2 Tissue Heart Valves-Pipeline Products by Stage of Development 15

5 Tissue Heart Valves Companies and Product Overview 17

5.1 Abbott Vascular Inc Company Overview 17

5.2 Children's Hospital Boston Company Overview 20

5.3 Colibri Heart Valve, LLC Company Overview 21

5.4 CorMatrix Cardiovascular Inc Company Overview 23

5.5 CryoLife Inc Company Overview 28

5.6 Cytograft Tissue Engineering Inc (Inactive) Company Overview 30

5.7 Daidalos Solutions BV Company Overview 31

5.8 Edwards Lifesciences Corp Company Overview 34

5.9 Hancock Jaffe Laboratories Inc Company Overview 42

5.10 LivaNova PLC Company Overview 44

5.11 Medtronic plc Company Overview 52

5.12 Revivicor Inc Company Overview 54

5.13 Sree Chitra Tirunal Institute for Medical Sciences & Technology Company Overview 55

5.14 Stellenbosch University Company Overview 56

5.15 Tissue Regenix Ltd Company Overview 57

5.16 University of California Irvine Company Overview 59

5.17 University of Cambridge Company Overview 61

5.18 University of Minnesota Company Overview 62

5.19 University of Zurich Company Overview 63

5.20 ValveXchange, Inc. (Inactive) Company Overview 64

5.21 VueKlar Cardiovascular Ltd (Inactive) Company Overview 67

6 Tissue Heart Valves- Recent Developments 68

6.1 Jun 05, 2018: Medtronic Presents Strategic Growth Roadmap at 2018 Investor Day; Outlines Plan to Create Shareholder Value 68

6.2 May 24, 2018: Medtronic Reports Fourth Quarter And Fiscal Year 2018 Financial Results 68

6.3 May 23, 2018: Abbott's Investigational Tendyne Device for Mitral Valve Replacement Demonstrates Positive Outcomes at 30 Days in Global Study 71

6.4 May 09, 2018: Computer-Designed Customized Regenerative Heart Valves 72

6.5 May 07, 2018: Medtronic Appoints Mike Weinstein As Senior Vice President Of Strategy 73

6.6 May 02, 2018: CryoLife Announces First Quarter 2018 Financial Results 74

6.7 Apr 24, 2018: Edwards Lifesciences Announces First Quarter 2018 Financial Results 75

6.8 Apr 10, 2018: SUMMIT Trial (U.S. IDE) of the Tendyne Mitral Valve Received Approval From the FDA 76

6.9 Apr 05, 2018: Dr. Laura Mauri to Join Medtronic as Vice President, Global Clinical Research & Analytics 77

6.10 Mar 26, 2018: Tissue Regenix: Annual results for period ended 31 December 2017 77

6.11 Mar 22, 2018: LivaNova Announces Enrollment for PERFECT Perceval Valve Clinical Trial in China 79

6.12 Mar 08, 2018: Tissue Regenix: Full-year 2017 80

6.13 Mar 07, 2018: CryoLife Reports Fourth Quarter and Full Year 2017 Results 82

6.14 Feb 28, 2018: LivaNova Announces Fourth Quarter and Full-Year 2017 Results 83

6.15 Feb 07, 2018: Caisson Interventional Expanding in Maple Grove 85

6.16 Feb 02, 2018: JenaValve Technology Appoints Laura A. Brenton as Vice President of Clinical and International Market Development 86

6.17 Feb 01, 2018: Edwards Lifesciences Reports Fourth Quarter Results 87

6.18 Jan 30, 2018: Alex Gu Named Senior Vice President and President of Medtronic's Greater China Region 88

6.19 Jan 25, 2018: Edwards' INSPIRIS RESILIA Valve Approved In Canada 89

6.20 Jan 11, 2018: LivaNova Initiates BELIEVE Aortic Heart Valve Study in the U.S. and Canada 89

6.21 Jan 08, 2018: LivaNova Announces Matthew J. Dodds as Senior Vice President, Corporate Development 90

6.22 Dec 19, 2017: Bob White Named Executive Vice President and President of Medtronic's Minimally Invasive Therapies Group; Chris Lee to Assume Leadership of Medtronic's Asia Pacific Region 91

6.23 Dec 07, 2017: Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference 92

6.24 Dec 01, 2017: Tissue Regenix: Directorate Change 93

6.25 Nov 21, 2017: Medtronic Reports Second Quarter Financial Results 93

6.26 Nov 21, 2017: Vickie Capps Joins OmniGuide's Board of Directors 96

6.27 Nov 08, 2017: Medtronic Announces Preliminary Second Quarter Revenue 97

6.28 Nov 02, 2017: Medtronic Releases Fiscal Year 2017 Integrated Performance Report 98

6.29 Nov 02, 2017: Tissue Regenix: Steve Couldwell appointed Group CEO 99

6.30 Nov 02, 2017: LivaNova Reports Third Quarter 2017 Results 99

6.31 Nov 01, 2017: New tissue-engineered blood vessel replacements closer to human trials 101

6.32 Oct 30, 2017: CryoLife Reports Third Quarter 2017 Results 102

6.33 Oct 24, 2017: Edwards Lifesciences Announces Third Quarter Results 104

6.34 Oct 06, 2017: Medtronic Provides Update on Impact from Hurricane Maria 105

6.35 Oct 02, 2017: Jeffrey H. Burbank Joins CryoLife Board of Directors 106

6.36 Sep 24, 2017: Edwards Announces Key Events For PCR London Valves 2017 107

6.37 Sep 11, 2017: LivaNova Announces Publication of Literature Review Highlighting the Clinical Value and Safety of the Perceval Sutureless Valve for Aortic Valve Replacement 108

6.38 Aug 23, 2017: OmniGuide Appoints Ajay Bhave as its Chief Technology Officer 108

6.39 Aug 22, 2017: Medtronic Reports First Quarter Financial Results 109

6.40 Aug 09, 2017: LivaNova Reports Second Quarter 2017 Results 111

6.41 Aug 04, 2017: LivaNovas Perceval Sutureless Aortic Heart Valve Awarded New Technology Add-on Payment from the Center for Medicare and Medicaid Services 113

6.42 Aug 02, 2017: Medtronic Expands Heart Valve Portfolio with FDA Approval and CE Mark of the Avalus Surgical Aortic Valve 113

6.43 Jul 26, 2017: Edwards Lifesciences Reports Second Quarter Results 114

6.44 Jul 24, 2017: CryoLife Reports Second Quarter 2017 Financial Results 116

6.45 Jul 05, 2017: Edward's INSPIRIS RESILIA Valve Receives FDA Approval 117

6.46 Jun 12, 2017: LivaNova Appoints Keyna Skeffington as Senior Vice President and General Counsel 118

7 Appendix 119

7.1 Methodology 119

7.2 About GlobalData 122

7.3 Contact Us 122

7.4 Disclaimer 122


List Of Figure

1.2 List of Figures

Figure 1: Tissue Heart Valves-Pipeline Products by Stage of Development 9

Figure 2: Tissue Heart Valves-Pipeline Products by Segment 10

Figure 3: Tissue Heart Valves-Pipeline Products by Territory 11

Figure 4: Tissue Heart Valves-Pipeline Products by Regulatory Path 12

Figure 5: Tissue Heart Valves-Pipeline Products by Estimated Approval Date 13

Figure 6: Tissue Heart Valves-Ongoing Clinical Trials 14


List Of Table

1.1 List of Tables

Table 1: Tissue Heart Valves-Pipeline Products by Stage of Development 9

Table 2: Tissue Heart Valves-Pipeline Products by Segment 10

Table 3: Tissue Heart Valves-Pipeline Products by Territory 11

Table 4: Tissue Heart Valves-Pipeline Products by Regulatory Path 12

Table 5: Tissue Heart Valves-Pipeline Products by Estimated Approval Date 13

Table 6: Tissue Heart Valves-Ongoing Clinical Trials 14

Table 7: Tissue Heart Valves Companies-Pipeline Products by Stage of Development 15

Table 8: Tissue Heart Valves-Pipeline Products by Stage of Development 16

Table 9: Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 18

Table 10: Tendyne Bioprosthetic Mitral Valve Implantation System-Product Status 18

Table 11: Tendyne Bioprosthetic Mitral Valve Implantation System-Product Description 18

Table 12: Abbott Vascular Inc-Ongoing Clinical Trials Overview 19

Table 13: Tendyne Bioprosthetic Mitral Valve Implantation System-Expanded Clinical Study of the Tendyne Mitral Valve System 20

Table 14: Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 21

Table 15: Heart Valve Leaflet-Product Status 21

Table 16: Heart Valve Leaflet-Product Description 21

Table 17: Colibri Heart Valve, LLC Pipeline Products & Ongoing Clinical Trials Overview 22

Table 18: Pulmonary Valve-Product Status 22

Table 19: Pulmonary Valve-Product Description 22

Table 20: Sutureless Surgical Aortic Valve-Product Status 23

Table 21: Sutureless Surgical Aortic Valve-Product Description 23

Table 22: CorMatrix Cardiovascular Inc Pipeline Products & Ongoing Clinical Trials Overview 24

Table 23: CorMatrix ECM-Heart Valve Repair-Product Status 24

Table 24: CorMatrix ECM-Heart Valve Repair-Product Description 24

Table 25: CorMatrix ECM-Heart Valve Replacement-Product Status 25

Table 26: CorMatrix ECM-Heart Valve Replacement-Product Description 25

Table 27: CorMatrix ECM Tricuspid Heart Valve-Product Status 25

Table 28: CorMatrix ECM Tricuspid Heart Valve-Product Description 26

Table 29: Regenerating Tubular Mitral Valve-Product Status 26

Table 30: Regenerating Tubular Mitral Valve-Product Description 26

Table 31: CorMatrix Cardiovascular Inc-Ongoing Clinical Trials Overview 27

Table 32: CorMatrix ECM Tricuspid Heart Valve-CorMatrix ECM Tricuspid Valve Replacement Safety and Early Feasibility 28

Table 33: CryoLife Inc Pipeline Products & Ongoing Clinical Trials Overview 29

Table 34: CryoValve SGAV-Product Status 29

Table 35: CryoValve SGAV-Product Description 29

Table 36: Synergraft Xenograft Heart Valve-Product Status 30

Table 37: Synergraft Xenograft Heart Valve-Product Description 30

Table 38: Cytograft Tissue Engineering Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 31

Table 39: Cytograft Valve-Product Status 31

Table 40: Cytograft Valve-Product Description 31

Table 41: Daidalos Solutions BV Pipeline Products & Ongoing Clinical Trials Overview 32

Table 42: Sutureless Aortic valve Prosthesis-Product Status 32

Table 43: Sutureless Aortic valve Prosthesis-Product Description 32

Table 44: Sutureless Mitral Valve Prostheses-Product Status 33

Table 45: Sutureless Mitral Valve Prostheses-Product Description 33

Table 46: Sutureless Tricuspid Valve Prostheses-Product Status 33

Table 47: Sutureless Tricuspid Valve Prostheses-Product Description 34

Table 48: Edwards Lifesciences Corp Pipeline Products & Ongoing Clinical Trials Overview 35

Table 49: GLX Aortic Conduit-Product Status 35

Table 50: GLX Aortic Conduit-Product Description 35

Table 51: INSPIRIS RESILIA Aortic Valve-Product Status 36

Table 52: INSPIRIS RESILIA Aortic Valve-Product Description 36

Table 53: INTUITY Valve System-Product Status 36

Table 54: INTUITY Valve System-Product Description 37

Table 55: KONECT Conduit-Product Status 37

Table 56: KONECT Conduit-Product Description 37

Table 57: Magna EASE Surgical Valve With GLX-Product Status 38

Table 58: Magna EASE Surgical Valve With GLX-Product Description 38

Table 59: Edwards Lifesciences Corp-Ongoing Clinical Trials Overview 39

Table 60: INTUITY Valve System-Multi-center Experience with the Rapid Deployment Edwards INTUITY Valve System for Aortic Valve Replacement 40

Table 61: INTUITY Valve System-Surgical Treatment of Aortic Stenosis with a Next Generation Surgical Aortic Valve 40

Table 62: Magna EASE Surgical Valve With GLX-Clinical Study to Evaluate the Performance of Magna Ease Heart Valve in Chinese Patients 41

Table 63: Magna EASE Surgical Valve With GLX-Prospective, Non-randomized, Multicenter Clinical Evaluation of the Edwards Pericardial Aortic and Mitral Bioprostheses (Models 11000a and 11000m) with a New Tissue Treatment Platform: COMMENCE 41

Table 64: INSPIRIS RESILIA Aortic Valve-Prospective, Non-randomized, Multicenter Clinical Evaluation of the Edwards Pericardial Aortic and Mitral Bioprostheses (Models 11000a and 11000m) with a New Tissue Treatment Platform: COMMENCE 42

Table 65: Hancock Jaffe Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 43

Table 66: Bioprosthetic Aortic Heart Valve-Product Status 43

Table 67: Bioprosthetic Aortic Heart Valve-Product Description 43

Table 68: Bioprosthetic Mitral Heart Valve-Product Status 44

Table 69: Bioprosthetic Mitral Heart Valve-Product Description 44

Table 70: LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview 45

Table 71: Perceval S-Extended Indications-Product Status 45

Table 72: Perceval S-Extended Indications-Product Description 46

Table 73: Perceval Sutureless Aortic Valve-XL Version-Product Status 46

Table 74: Perceval Sutureless Aortic Valve-XL Version-Product Description 46

Table 75: Perceval Sutureless Heart Valve-Product Status 47

Table 76: Perceval Sutureless Heart Valve-Product Description 47

Table 77: LivaNova PLC-Ongoing Clinical Trials Overview 48

Table 78: Perceval Sutureless Heart Valve-Behavior of Valve Leaflets and the Incidence of Reduced Mobility Post-surgical Aortic Valve Implant 49

Table 79: Perceval Sutureless Heart Valve-Perceval S Valve Clinical Trial for Extended CE Mark 49

Table 80: Perceval Sutureless Heart Valve-Perceval Sutureless Implant Versus Standard-aortic Valve Replacement A Controlled Randomized Trial in the Surgical Treatment of Aortic Valve Disease 49

Table 81: Perceval Sutureless Heart Valve-Perceval Valve Clinical study for Chinese Registration: PERFECT Trial 50

Table 82: Perceval S-Extended Indications-Behavior of Valve Leaflets and the Incidence of Reduced Mobility Post-surgical Aortic Valve Implant 51

Table 83: Perceval Sutureless Aortic Valve-XL Version-Behavior of Valve Leaflets and the Incidence of Reduced Mobility Post-surgical Aortic Valve Implant 52

Table 84: Perceval Sutureless Aortic Valve-XL Version-Perceval Sutureless Implant Versus Standard-aortic Valve Replacement A Controlled Randomized Trial in the Surgical Treatment of Aortic Valve Disease 52

Table 85: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 53

Table 86: Closed-Chest Aortic Tissue Valve-Product Status 53

Table 87: Closed-Chest Aortic Tissue Valve-Product Description 53

Table 88: Enable Valve-Beating Heart Procedure-Product Status 54

Table 89: Enable Valve-Beating Heart Procedure-Product Description 54

Table 90: Revivicor Inc Pipeline Products & Ongoing Clinical Trials Overview 55

Table 91: Heart Valve-Product Status 55

Table 92: Heart Valve-Product Description 55

Table 93: Sree Chitra Tirunal Institute for Medical Sciences & Technology Pipeline Products & Ongoing Clinical Trials Overview 56

Table 94: Tissue Based Cardiac Valve-Product Status 56

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Abbott Vascular Inc, Tendyne Bioprosthetic Mitral Valve Implantation System; Children's Hospital Boston, Heart Valve Leaflet; Colibri Heart Valve, LLC, Pulmonary Valve; Colibri Heart Valve, LLC, Sutureless Surgical Aortic Valve; CorMatrix Cardiovascular Inc, CorMatrix ECM - Heart Valve Repair; CorMatrix Cardiovascular Inc, CorMatrix ECM - Heart Valve Replacement; CorMatrix Cardiovascular Inc, CorMatrix ECM Tricuspid Heart Valve; CorMatrix Cardiovascular Inc, Regenerating Tubular Mitral Valve; CryoLife Inc, CryoValve SGAV; CryoLife Inc, Synergraft Xenograft Heart Valve; Cytograft Tissue Engineering Inc (Inactive), Cytograft Valve; Daidalos Solutions BV, Sutureless Aortic valve Prosthesis; Daidalos Solutions BV, Sutureless Mitral Valve Prostheses; Daidalos Solutions BV, Sutureless Tricuspid Valve Prostheses; Edwards Lifesciences Corp, GLX Aortic Conduit; Edwards Lifesciences Corp, INSPIRIS RESILIA Aortic Valve; Edwards Lifesciences Corp, INTUITY Valve System; Edwards Lifesciences Corp, KONECT Conduit; Edwards Lifesciences Corp, Magna EASE Surgical Valve With GLX; Hancock Jaffe Laboratories Inc, Bioprosthetic Aortic Heart Valve; Hancock Jaffe Laboratories Inc, Bioprosthetic Mitral Heart Valve; LivaNova PLC , Perceval S - Extended Indications; LivaNova PLC , Perceval Sutureless Aortic Valve - XL Version; LivaNova PLC , Perceval Sutureless Heart Valve; Medtronic plc, Closed-Chest Aortic Tissue Valve; Medtronic plc, Enable Valve-Beating Heart Procedure; Revivicor Inc, Heart Valve; Sree Chitra Tirunal Institute for Medical Sciences &; Technology, Tissue Based Cardiac Valve; Stellenbosch University, Percutaneous Heart Valve; Tissue Regenix Ltd, Cardiopure - Aortic Heart Valve; Tissue Regenix Ltd, Cardiopure - Pulmonary Heart Valve; University of California Irvine, Bileaflet Bioprosthetic Mitral Valve; University of California Irvine, Heart Valve Leaflets; University of Cambridge, Polymeric Heart Valve; University of Minnesota, Tissue-Engineered Vessel Graft; University of Zurich, Prostheses Heart Valve; ValveXchange, Inc. (Inactive), Vanguard System; ValveXchange, Inc. (Inactive), Vitality Exchangeable Valve System; ValveXchange, Inc. (Inactive), VXi Vanguard II; VueKlar Cardiovascular Ltd (Inactive), MR-Enhancing Percutaneous Heart Valve


Companies

Abbott Vascular Inc

Children's Hospital Boston

Colibri Heart Valve, LLC

CorMatrix Cardiovascular Inc

CryoLife Inc

Cytograft Tissue Engineering Inc

Daidalos Solutions BV

Edwards Lifesciences Corp

Hancock Jaffe Laboratories Inc

LivaNova PLC

Medtronic plc

Revivicor Inc

Sree Chitra Tirunal Institute for Medical Sciences & Technology

Stellenbosch University

Tissue Regenix Ltd

University of California Irvine

University of Cambridge

University of Minnesota

University of Zurich

ValveXchange, Inc.

VueKlar Cardiovascular Ltd

Tissue Heart Valves-Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, Tissue Heart Valves-Medical Devices Pipeline Assessment, 2018 provides an overview of Tissue Heart Valves currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Tissue Heart Valves pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Tissue Heart Valves under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Tissue Heart Valves and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry

Reasons to buy

The report enables you to-

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Tissue Heart Valves under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date

READ MORE

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 6

2 Introduction 7

2.1 Tissue Heart Valves Overview 7

3 Products under Development 8

3.1 Tissue Heart Valves-Pipeline Products by Stage of Development 8

3.2 Tissue Heart Valves-Pipeline Products by Segment 9

3.3 Tissue Heart Valves-Pipeline Products by Territory 10

3.4 Tissue Heart Valves-Pipeline Products by Regulatory Path 11

3.5 Tissue Heart Valves-Pipeline Products by Estimated Approval Date 12

3.6 Tissue Heart Valves-Ongoing Clinical Trials 13

4 Tissue Heart Valves-Pipeline Products under Development by Companies 14

4.1 Tissue Heart Valves Companies-Pipeline Products by Stage of Development 14

4.2 Tissue Heart Valves-Pipeline Products by Stage of Development 15

5 Tissue Heart Valves Companies and Product Overview 17

5.1 Abbott Vascular Inc Company Overview 17

5.2 Children's Hospital Boston Company Overview 20

5.3 Colibri Heart Valve, LLC Company Overview 21

5.4 CorMatrix Cardiovascular Inc Company Overview 23

5.5 CryoLife Inc Company Overview 28

5.6 Cytograft Tissue Engineering Inc (Inactive) Company Overview 30

5.7 Daidalos Solutions BV Company Overview 31

5.8 Edwards Lifesciences Corp Company Overview 34

5.9 Hancock Jaffe Laboratories Inc Company Overview 42

5.10 LivaNova PLC Company Overview 44

5.11 Medtronic plc Company Overview 52

5.12 Revivicor Inc Company Overview 54

5.13 Sree Chitra Tirunal Institute for Medical Sciences & Technology Company Overview 55

5.14 Stellenbosch University Company Overview 56

5.15 Tissue Regenix Ltd Company Overview 57

5.16 University of California Irvine Company Overview 59

5.17 University of Cambridge Company Overview 61

5.18 University of Minnesota Company Overview 62

5.19 University of Zurich Company Overview 63

5.20 ValveXchange, Inc. (Inactive) Company Overview 64

5.21 VueKlar Cardiovascular Ltd (Inactive) Company Overview 67

6 Tissue Heart Valves- Recent Developments 68

6.1 Jun 05, 2018: Medtronic Presents Strategic Growth Roadmap at 2018 Investor Day; Outlines Plan to Create Shareholder Value 68

6.2 May 24, 2018: Medtronic Reports Fourth Quarter And Fiscal Year 2018 Financial Results 68

6.3 May 23, 2018: Abbott's Investigational Tendyne Device for Mitral Valve Replacement Demonstrates Positive Outcomes at 30 Days in Global Study 71

6.4 May 09, 2018: Computer-Designed Customized Regenerative Heart Valves 72

6.5 May 07, 2018: Medtronic Appoints Mike Weinstein As Senior Vice President Of Strategy 73

6.6 May 02, 2018: CryoLife Announces First Quarter 2018 Financial Results 74

6.7 Apr 24, 2018: Edwards Lifesciences Announces First Quarter 2018 Financial Results 75

6.8 Apr 10, 2018: SUMMIT Trial (U.S. IDE) of the Tendyne Mitral Valve Received Approval From the FDA 76

6.9 Apr 05, 2018: Dr. Laura Mauri to Join Medtronic as Vice President, Global Clinical Research & Analytics 77

6.10 Mar 26, 2018: Tissue Regenix: Annual results for period ended 31 December 2017 77

6.11 Mar 22, 2018: LivaNova Announces Enrollment for PERFECT Perceval Valve Clinical Trial in China 79

6.12 Mar 08, 2018: Tissue Regenix: Full-year 2017 80

6.13 Mar 07, 2018: CryoLife Reports Fourth Quarter and Full Year 2017 Results 82

6.14 Feb 28, 2018: LivaNova Announces Fourth Quarter and Full-Year 2017 Results 83

6.15 Feb 07, 2018: Caisson Interventional Expanding in Maple Grove 85

6.16 Feb 02, 2018: JenaValve Technology Appoints Laura A. Brenton as Vice President of Clinical and International Market Development 86

6.17 Feb 01, 2018: Edwards Lifesciences Reports Fourth Quarter Results 87

6.18 Jan 30, 2018: Alex Gu Named Senior Vice President and President of Medtronic's Greater China Region 88

6.19 Jan 25, 2018: Edwards' INSPIRIS RESILIA Valve Approved In Canada 89

6.20 Jan 11, 2018: LivaNova Initiates BELIEVE Aortic Heart Valve Study in the U.S. and Canada 89

6.21 Jan 08, 2018: LivaNova Announces Matthew J. Dodds as Senior Vice President, Corporate Development 90

6.22 Dec 19, 2017: Bob White Named Executive Vice President and President of Medtronic's Minimally Invasive Therapies Group; Chris Lee to Assume Leadership of Medtronic's Asia Pacific Region 91

6.23 Dec 07, 2017: Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference 92

6.24 Dec 01, 2017: Tissue Regenix: Directorate Change 93

6.25 Nov 21, 2017: Medtronic Reports Second Quarter Financial Results 93

6.26 Nov 21, 2017: Vickie Capps Joins OmniGuide's Board of Directors 96

6.27 Nov 08, 2017: Medtronic Announces Preliminary Second Quarter Revenue 97

6.28 Nov 02, 2017: Medtronic Releases Fiscal Year 2017 Integrated Performance Report 98

6.29 Nov 02, 2017: Tissue Regenix: Steve Couldwell appointed Group CEO 99

6.30 Nov 02, 2017: LivaNova Reports Third Quarter 2017 Results 99

6.31 Nov 01, 2017: New tissue-engineered blood vessel replacements closer to human trials 101

6.32 Oct 30, 2017: CryoLife Reports Third Quarter 2017 Results 102

6.33 Oct 24, 2017: Edwards Lifesciences Announces Third Quarter Results 104

6.34 Oct 06, 2017: Medtronic Provides Update on Impact from Hurricane Maria 105

6.35 Oct 02, 2017: Jeffrey H. Burbank Joins CryoLife Board of Directors 106

6.36 Sep 24, 2017: Edwards Announces Key Events For PCR London Valves 2017 107

6.37 Sep 11, 2017: LivaNova Announces Publication of Literature Review Highlighting the Clinical Value and Safety of the Perceval Sutureless Valve for Aortic Valve Replacement 108

6.38 Aug 23, 2017: OmniGuide Appoints Ajay Bhave as its Chief Technology Officer 108

6.39 Aug 22, 2017: Medtronic Reports First Quarter Financial Results 109

6.40 Aug 09, 2017: LivaNova Reports Second Quarter 2017 Results 111

6.41 Aug 04, 2017: LivaNovas Perceval Sutureless Aortic Heart Valve Awarded New Technology Add-on Payment from the Center for Medicare and Medicaid Services 113

6.42 Aug 02, 2017: Medtronic Expands Heart Valve Portfolio with FDA Approval and CE Mark of the Avalus Surgical Aortic Valve 113

6.43 Jul 26, 2017: Edwards Lifesciences Reports Second Quarter Results 114

6.44 Jul 24, 2017: CryoLife Reports Second Quarter 2017 Financial Results 116

6.45 Jul 05, 2017: Edward's INSPIRIS RESILIA Valve Receives FDA Approval 117

6.46 Jun 12, 2017: LivaNova Appoints Keyna Skeffington as Senior Vice President and General Counsel 118

7 Appendix 119

7.1 Methodology 119

7.2 About GlobalData 122

7.3 Contact Us 122

7.4 Disclaimer 122


List Of Figure

1.2 List of Figures

Figure 1: Tissue Heart Valves-Pipeline Products by Stage of Development 9

Figure 2: Tissue Heart Valves-Pipeline Products by Segment 10

Figure 3: Tissue Heart Valves-Pipeline Products by Territory 11

Figure 4: Tissue Heart Valves-Pipeline Products by Regulatory Path 12

Figure 5: Tissue Heart Valves-Pipeline Products by Estimated Approval Date 13

Figure 6: Tissue Heart Valves-Ongoing Clinical Trials 14


List Of Table

1.1 List of Tables

Table 1: Tissue Heart Valves-Pipeline Products by Stage of Development 9

Table 2: Tissue Heart Valves-Pipeline Products by Segment 10

Table 3: Tissue Heart Valves-Pipeline Products by Territory 11

Table 4: Tissue Heart Valves-Pipeline Products by Regulatory Path 12

Table 5: Tissue Heart Valves-Pipeline Products by Estimated Approval Date 13

Table 6: Tissue Heart Valves-Ongoing Clinical Trials 14

Table 7: Tissue Heart Valves Companies-Pipeline Products by Stage of Development 15

Table 8: Tissue Heart Valves-Pipeline Products by Stage of Development 16

Table 9: Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 18

Table 10: Tendyne Bioprosthetic Mitral Valve Implantation System-Product Status 18

Table 11: Tendyne Bioprosthetic Mitral Valve Implantation System-Product Description 18

Table 12: Abbott Vascular Inc-Ongoing Clinical Trials Overview 19

Table 13: Tendyne Bioprosthetic Mitral Valve Implantation System-Expanded Clinical Study of the Tendyne Mitral Valve System 20

Table 14: Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 21

Table 15: Heart Valve Leaflet-Product Status 21

Table 16: Heart Valve Leaflet-Product Description 21

Table 17: Colibri Heart Valve, LLC Pipeline Products & Ongoing Clinical Trials Overview 22

Table 18: Pulmonary Valve-Product Status 22

Table 19: Pulmonary Valve-Product Description 22

Table 20: Sutureless Surgical Aortic Valve-Product Status 23

Table 21: Sutureless Surgical Aortic Valve-Product Description 23

Table 22: CorMatrix Cardiovascular Inc Pipeline Products & Ongoing Clinical Trials Overview 24

Table 23: CorMatrix ECM-Heart Valve Repair-Product Status 24

Table 24: CorMatrix ECM-Heart Valve Repair-Product Description 24

Table 25: CorMatrix ECM-Heart Valve Replacement-Product Status 25

Table 26: CorMatrix ECM-Heart Valve Replacement-Product Description 25

Table 27: CorMatrix ECM Tricuspid Heart Valve-Product Status 25

Table 28: CorMatrix ECM Tricuspid Heart Valve-Product Description 26

Table 29: Regenerating Tubular Mitral Valve-Product Status 26

Table 30: Regenerating Tubular Mitral Valve-Product Description 26

Table 31: CorMatrix Cardiovascular Inc-Ongoing Clinical Trials Overview 27

Table 32: CorMatrix ECM Tricuspid Heart Valve-CorMatrix ECM Tricuspid Valve Replacement Safety and Early Feasibility 28

Table 33: CryoLife Inc Pipeline Products & Ongoing Clinical Trials Overview 29

Table 34: CryoValve SGAV-Product Status 29

Table 35: CryoValve SGAV-Product Description 29

Table 36: Synergraft Xenograft Heart Valve-Product Status 30

Table 37: Synergraft Xenograft Heart Valve-Product Description 30

Table 38: Cytograft Tissue Engineering Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 31

Table 39: Cytograft Valve-Product Status 31

Table 40: Cytograft Valve-Product Description 31

Table 41: Daidalos Solutions BV Pipeline Products & Ongoing Clinical Trials Overview 32

Table 42: Sutureless Aortic valve Prosthesis-Product Status 32

Table 43: Sutureless Aortic valve Prosthesis-Product Description 32

Table 44: Sutureless Mitral Valve Prostheses-Product Status 33

Table 45: Sutureless Mitral Valve Prostheses-Product Description 33

Table 46: Sutureless Tricuspid Valve Prostheses-Product Status 33

Table 47: Sutureless Tricuspid Valve Prostheses-Product Description 34

Table 48: Edwards Lifesciences Corp Pipeline Products & Ongoing Clinical Trials Overview 35

Table 49: GLX Aortic Conduit-Product Status 35

Table 50: GLX Aortic Conduit-Product Description 35

Table 51: INSPIRIS RESILIA Aortic Valve-Product Status 36

Table 52: INSPIRIS RESILIA Aortic Valve-Product Description 36

Table 53: INTUITY Valve System-Product Status 36

Table 54: INTUITY Valve System-Product Description 37

Table 55: KONECT Conduit-Product Status 37

Table 56: KONECT Conduit-Product Description 37

Table 57: Magna EASE Surgical Valve With GLX-Product Status 38

Table 58: Magna EASE Surgical Valve With GLX-Product Description 38

Table 59: Edwards Lifesciences Corp-Ongoing Clinical Trials Overview 39

Table 60: INTUITY Valve System-Multi-center Experience with the Rapid Deployment Edwards INTUITY Valve System for Aortic Valve Replacement 40

Table 61: INTUITY Valve System-Surgical Treatment of Aortic Stenosis with a Next Generation Surgical Aortic Valve 40

Table 62: Magna EASE Surgical Valve With GLX-Clinical Study to Evaluate the Performance of Magna Ease Heart Valve in Chinese Patients 41

Table 63: Magna EASE Surgical Valve With GLX-Prospective, Non-randomized, Multicenter Clinical Evaluation of the Edwards Pericardial Aortic and Mitral Bioprostheses (Models 11000a and 11000m) with a New Tissue Treatment Platform: COMMENCE 41

Table 64: INSPIRIS RESILIA Aortic Valve-Prospective, Non-randomized, Multicenter Clinical Evaluation of the Edwards Pericardial Aortic and Mitral Bioprostheses (Models 11000a and 11000m) with a New Tissue Treatment Platform: COMMENCE 42

Table 65: Hancock Jaffe Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 43

Table 66: Bioprosthetic Aortic Heart Valve-Product Status 43

Table 67: Bioprosthetic Aortic Heart Valve-Product Description 43

Table 68: Bioprosthetic Mitral Heart Valve-Product Status 44

Table 69: Bioprosthetic Mitral Heart Valve-Product Description 44

Table 70: LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview 45

Table 71: Perceval S-Extended Indications-Product Status 45

Table 72: Perceval S-Extended Indications-Product Description 46

Table 73: Perceval Sutureless Aortic Valve-XL Version-Product Status 46

Table 74: Perceval Sutureless Aortic Valve-XL Version-Product Description 46

Table 75: Perceval Sutureless Heart Valve-Product Status 47

Table 76: Perceval Sutureless Heart Valve-Product Description 47

Table 77: LivaNova PLC-Ongoing Clinical Trials Overview 48

Table 78: Perceval Sutureless Heart Valve-Behavior of Valve Leaflets and the Incidence of Reduced Mobility Post-surgical Aortic Valve Implant 49

Table 79: Perceval Sutureless Heart Valve-Perceval S Valve Clinical Trial for Extended CE Mark 49

Table 80: Perceval Sutureless Heart Valve-Perceval Sutureless Implant Versus Standard-aortic Valve Replacement A Controlled Randomized Trial in the Surgical Treatment of Aortic Valve Disease 49

Table 81: Perceval Sutureless Heart Valve-Perceval Valve Clinical study for Chinese Registration: PERFECT Trial 50

Table 82: Perceval S-Extended Indications-Behavior of Valve Leaflets and the Incidence of Reduced Mobility Post-surgical Aortic Valve Implant 51

Table 83: Perceval Sutureless Aortic Valve-XL Version-Behavior of Valve Leaflets and the Incidence of Reduced Mobility Post-surgical Aortic Valve Implant 52

Table 84: Perceval Sutureless Aortic Valve-XL Version-Perceval Sutureless Implant Versus Standard-aortic Valve Replacement A Controlled Randomized Trial in the Surgical Treatment of Aortic Valve Disease 52

Table 85: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 53

Table 86: Closed-Chest Aortic Tissue Valve-Product Status 53

Table 87: Closed-Chest Aortic Tissue Valve-Product Description 53

Table 88: Enable Valve-Beating Heart Procedure-Product Status 54

Table 89: Enable Valve-Beating Heart Procedure-Product Description 54

Table 90: Revivicor Inc Pipeline Products & Ongoing Clinical Trials Overview 55

Table 91: Heart Valve-Product Status 55

Table 92: Heart Valve-Product Description 55

Table 93: Sree Chitra Tirunal Institute for Medical Sciences & Technology Pipeline Products & Ongoing Clinical Trials Overview 56

Table 94: Tissue Based Cardiac Valve-Product Status 56

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Abbott Vascular Inc, Tendyne Bioprosthetic Mitral Valve Implantation System; Children's Hospital Boston, Heart Valve Leaflet; Colibri Heart Valve, LLC, Pulmonary Valve; Colibri Heart Valve, LLC, Sutureless Surgical Aortic Valve; CorMatrix Cardiovascular Inc, CorMatrix ECM - Heart Valve Repair; CorMatrix Cardiovascular Inc, CorMatrix ECM - Heart Valve Replacement; CorMatrix Cardiovascular Inc, CorMatrix ECM Tricuspid Heart Valve; CorMatrix Cardiovascular Inc, Regenerating Tubular Mitral Valve; CryoLife Inc, CryoValve SGAV; CryoLife Inc, Synergraft Xenograft Heart Valve; Cytograft Tissue Engineering Inc (Inactive), Cytograft Valve; Daidalos Solutions BV, Sutureless Aortic valve Prosthesis; Daidalos Solutions BV, Sutureless Mitral Valve Prostheses; Daidalos Solutions BV, Sutureless Tricuspid Valve Prostheses; Edwards Lifesciences Corp, GLX Aortic Conduit; Edwards Lifesciences Corp, INSPIRIS RESILIA Aortic Valve; Edwards Lifesciences Corp, INTUITY Valve System; Edwards Lifesciences Corp, KONECT Conduit; Edwards Lifesciences Corp, Magna EASE Surgical Valve With GLX; Hancock Jaffe Laboratories Inc, Bioprosthetic Aortic Heart Valve; Hancock Jaffe Laboratories Inc, Bioprosthetic Mitral Heart Valve; LivaNova PLC , Perceval S - Extended Indications; LivaNova PLC , Perceval Sutureless Aortic Valve - XL Version; LivaNova PLC , Perceval Sutureless Heart Valve; Medtronic plc, Closed-Chest Aortic Tissue Valve; Medtronic plc, Enable Valve-Beating Heart Procedure; Revivicor Inc, Heart Valve; Sree Chitra Tirunal Institute for Medical Sciences &; Technology, Tissue Based Cardiac Valve; Stellenbosch University, Percutaneous Heart Valve; Tissue Regenix Ltd, Cardiopure - Aortic Heart Valve; Tissue Regenix Ltd, Cardiopure - Pulmonary Heart Valve; University of California Irvine, Bileaflet Bioprosthetic Mitral Valve; University of California Irvine, Heart Valve Leaflets; University of Cambridge, Polymeric Heart Valve; University of Minnesota, Tissue-Engineered Vessel Graft; University of Zurich, Prostheses Heart Valve; ValveXchange, Inc. (Inactive), Vanguard System; ValveXchange, Inc. (Inactive), Vitality Exchangeable Valve System; ValveXchange, Inc. (Inactive), VXi Vanguard II; VueKlar Cardiovascular Ltd (Inactive), MR-Enhancing Percutaneous Heart Valve


Companies

Abbott Vascular Inc

Children's Hospital Boston

Colibri Heart Valve, LLC

CorMatrix Cardiovascular Inc

CryoLife Inc

Cytograft Tissue Engineering Inc

Daidalos Solutions BV

Edwards Lifesciences Corp

Hancock Jaffe Laboratories Inc

LivaNova PLC

Medtronic plc

Revivicor Inc

Sree Chitra Tirunal Institute for Medical Sciences & Technology

Stellenbosch University

Tissue Regenix Ltd

University of California Irvine

University of Cambridge

University of Minnesota

University of Zurich

ValveXchange, Inc.

VueKlar Cardiovascular Ltd